Last reviewed · How we verify
AK120
AK120 is an engineered T cell engager that redirects patient T cells to recognize and eliminate cancer cells expressing specific tumor antigens.
AK120 is an engineered T cell engager that redirects patient T cells to recognize and eliminate cancer cells expressing specific tumor antigens. Used for Solid tumors (specific indication under clinical evaluation in Phase 3).
At a glance
| Generic name | AK120 |
|---|---|
| Sponsor | Akesobio Australia Pty Ltd |
| Drug class | Bispecific T cell engager |
| Target | CD3 and tumor-associated antigen (specific target not publicly disclosed) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AK120 functions as a bispecific antibody construct that simultaneously binds to CD3 on T cells and to a tumor-associated antigen on cancer cells, bringing them into close proximity. This engagement activates the T cell receptor signaling cascade, enabling T cell proliferation, activation, and direct cytotoxic killing of the targeted cancer cells. The mechanism leverages the patient's own immune system to achieve anti-tumor effects.
Approved indications
- Solid tumors (specific indication under clinical evaluation in Phase 3)
Common side effects
- Cytokine release syndrome
- T cell activation-related toxicity
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis (PHASE1, PHASE2)
- Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis (PHASE2)
- A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (PHASE3)
- A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD) (PHASE2)
- A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis (PHASE3)
- A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK120 CI brief — competitive landscape report
- AK120 updates RSS · CI watch RSS
- Akesobio Australia Pty Ltd portfolio CI